Significance of Nanocarriers in Pulmonory Drug Delivery System
By seethasunkara - 10/31/2009
(16 votes)
The purpose of this review is to discuss the impact of nanocarriers administered by pulmonary route to treat and to diagnose respiratory and non respiratory diseases. Indeed, during the past 10 years, the removal of chlorofluorocarbon propellants from industrial and household products intended for the pulmonary route has lead to the developments of new alternative products. Amongst these ones, on one hand, a lot of attention has been focused to improve the bioavailability of marketed drugs intended for respiratory diseases and to develop new concepts for pulmonary administration of drugs and, on the other hand, to use the pulmonary route to administer drugs for systemic diseases. This has led to some marketed products through the last decade. Although the introduction of nanotechnology permitted to step over numerous problems and to improve the bioavailability of drugs, there are, however, unresolved delivery problems to be still addressed. These scientific and industrial innovations and challenges are discussed along this review together with an analysis of the current situation concerning the industrial developments.
Author profile page link: http://www.pharmainfo.net/seetha
Co-author profile page link : http://www.pharmainfo.net/ramesh-janga
Click to see next slide
hello Seetha.. nice
hello Seetha..
nice presentation..
what is the final fate of micelles, liposomes, nanoparticles & cyclodextrins in body & the major disadvantages related to them...
regards,
Sakshi.
Sakshi Agrawal
http://www.pharmainfo.net/sakshi-agrawal
Excellent
What is the influence of nanoparticles on cytotoxicity and what way it can be pre-vented?
ABHERI DAS SARMA
http://www.pharmainfo.net/abherids86
Dear Seetha Could you please
Dear Seetha
Could you please provide the size range of particles which are easily throwed out by sneezing from the respiratory tract?
Mr. Dixon Thomas, M. Pharm, M. S., RPh
http://www.pharmainfo.net/pharmacistdixon
hi
hi seetha
very nice presentation.
I want to know which are the marketed preparation available on these pulmonary drug delivery using nano carrier. In addition to that which are the future prospectives for PDDS ?
http://www.pharmainfo.net/pankajpatel
Hoe this nanocerrier can
Hoe this nanocerrier can better option than inhalation or oral therapy?
K.H.Patel.
My profile link is
http://www.pharmainfo.net/khushbu-hasmukh-patel
Question
Is there any examples of liposomal pulmonory drug delivery? how the core chemical is detoxified in liposomal pulmonory drug delivery system?
Nanocarriers base material and association properties
1. What is side effect of association properties of nanocarriers in pulmonary drug delivery?
2. What should be ideal criteria of base material for nanocarriers?
Dr.Sandeep Bhaskar Kale
http://www.pharmainfo.net/sanykale123
nanocarrier and toxicity
Dear Seetha,
Nanocarriers associated with toxicities and stability problems. How will you justify ?
Regards,
Amol
Amol
http://www.pharmainfo.net/amolsmalpani
Elimination!!
What is the disposition of the nanoparticles in the pulmonary route?
Hello sir......
Actually......... the Nano particles(NP) are much less phagocytized by AMs (ALVEOLAR MACROPHAGES)than large particles but are effectively removed from the lung surface into the interstitium. Even from these interstitial sites, they undergo AM-mediated long-term NP clearance to the larynx
unique topic
hi,
Pulmonary DDS is better to control drug pharmacokineics, pharmacodynamics...etc.How?
Local delivery Vs Systemic delivery
1. Nanocarriers for pulmonary drug delivery are used for local delivery or systemic action?
2. How nanocarriers are administered for pulmonary route?
3. Give some examples of carriers that can be admixed with nanoparticles for DPI preparation.
4. What is the relationship between particle size and aerodynamic velocity?
5. What is the preferable size of nanoparticle for deposition in alveoli?
6. Name some crosslinking agents employed for stabilization of micelles.
7. As there are different types of liposomes, which one will you prefer for pulmonary delivery?
marketed product for nanocarriers administered by pulmonary rout
Dear Seetha,
Please give some marketed products based on your topic?
Regards,
Amol
Amol
http://www.pharmainfo.net/amolsmalpani
current situation of impact of nanocarriers by pulmonary route
dear friend ,
what is the current situation of impact of nanocarriers administered by pulmonary route to treat and to diagnose respiratory and non respiratory diseases.
Amit Sharma
http://www.pharmainfo.net/pharmamit
preclinical or clinical data
Dear Seetha,
You are having any preclinical or clinical data with you that this method is useful in practice?
Varsha Bansode
http://www.pharmainfo.net/varsha-bansode
bioavailability of the drug
Dear Seetha,
Nice presentation,
can you tell me that how much is the bioavailability of the drug by this method?and as there are other methods like chemotherapy,surgery and etc what you think which one is the best for treating a lung cancer?
Varsha Bansode
http://www.pharmainfo.net/varsha-bansode
best nanocarrier among micelles, liposomes,micro-emulsion
your ppt is good.
Tell me about the best nanocarrier among the following..... micelles, liposomes,micro-emulsion , cyclodextrins which you had mentioned in your ppt & why....
Best wishes
Shobha Deepthikompella
http://www.pharmainfo.net/shobhadeepthi
How are the terms ultra-fine particles and nanoparticles related
Hello Seetha,
I have the following queries:
1.How do we evaluate potential risks of nanoparticles now, since we have at best only preliminary data on hazards from current studies?
2.How are the terms ultra-fine particles and nanoparticles related?
3.Also comment on If nanoparticles are inhaled, do they get into the brain?
Bhasker
http://www.pharmainfo.net/bhasker